Oncol-话题@MedSci

#Oncol#

2384篇内容 | 2450人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1866437, encodeId=8ca5186643e84, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后, objectType=article, longId=293025, objectId=724d293025d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=724d293025d7, replyNumber=0, likeNumber=44, createdTime=2022-03-18, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=724d293025d7, moduleTitle=Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=724d293025d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866495, encodeId=f58d1866495d7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：芳香酶抑制剂对比他莫昔芬治疗绝经前的ER阳性早期乳腺癌, objectType=article, longId=295172, objectId=0c822951e291, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c822951e291, replyNumber=0, likeNumber=77, createdTime=2022-03-12, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c822951e291, moduleTitle=Lancet Oncol：芳香酶抑制剂对比他莫昔芬治疗绝经前的ER阳性早期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c822951e291)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866081, encodeId=c15f1866081ad, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet oncol：派姆单抗联合西妥昔单抗治疗复发性/转移性HNSCC的疗效和安全性, objectType=article, longId=211288, objectId=122f21128838, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=122f21128838, replyNumber=0, likeNumber=70, createdTime=2022-01-27, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=122f21128838, moduleTitle=Lancet oncol：派姆单抗联合西妥昔单抗治疗复发性/转移性HNSCC的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=122f21128838)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866522, encodeId=a56e1866522c3, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Oncologist：RAS/BRAF野生型转移性结直肠癌(mCRC)患者中以抗EGFR为基础的再诱导治疗的疗效, objectType=article, longId=299377, objectId=94492993e786, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94492993e786, replyNumber=0, likeNumber=50, createdTime=2023-01-01, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94492993e786, moduleTitle=Oncologist：RAS/BRAF野生型转移性结直肠癌(mCRC)患者中以抗EGFR为基础的再诱导治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94492993e786)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866368, encodeId=55e61866368ca, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：Afatinib（阿法替尼）治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）的疗效：来自3个IIIb期研究的合并分析, objectType=article, longId=220865, objectId=1061220865c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1061220865c1, replyNumber=0, likeNumber=80, createdTime=2022-07-12, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1061220865c1, moduleTitle=Front Oncol：Afatinib（阿法替尼）治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）的疗效：来自3个IIIb期研究的合并分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1061220865c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866056, encodeId=d3ce1866056d2, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：本妥昔单抗维多丁可显著减少高危型霍奇金淋巴瘤儿童患者的放疗剂量且不影响疗效, objectType=article, longId=210468, objectId=7cd7210468a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cd7210468a5, replyNumber=0, likeNumber=65, createdTime=2021-04-30, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cd7210468a5, moduleTitle=J Clin Oncol：本妥昔单抗维多丁可显著减少高危型霍奇金淋巴瘤儿童患者的放疗剂量且不影响疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cd7210468a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866523, encodeId=f759186652302, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：伴有肺胸膜侵犯(VPI)的IB期NSCLC (≦3 cm)患者的手术治疗模式和预后, objectType=article, longId=299290, objectId=497b299290d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=497b299290d5, replyNumber=0, likeNumber=66, createdTime=2022-10-07, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=497b299290d5, moduleTitle=Front Oncol：伴有肺胸膜侵犯(VPI)的IB期NSCLC (≦3 cm)患者的手术治疗模式和预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=497b299290d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866363, encodeId=a756186636359, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Thorac Oncol：Durvalumab +tremelimumab联合或不联合化疗一线治疗驱动基因阴性的转移性NSCLC患者的疗效和安全性, objectType=article, longId=220795, objectId=abf7220e9596, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abf7220e9596, replyNumber=0, likeNumber=60, createdTime=2022-11-04, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abf7220e9596, moduleTitle=J Thorac Oncol：Durvalumab +tremelimumab联合或不联合化疗一线治疗驱动基因阴性的转移性NSCLC患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=abf7220e9596)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866255, encodeId=de6418662557a, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：不可切除的III期非小细胞肺癌同期或续贯放化疗后Durvalumab维持治疗的真实世界、多中心、观察性回顾性研究, objectType=article, longId=217894, objectId=d2e921e89470, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2e921e89470, replyNumber=0, likeNumber=123, createdTime=2022-06-20, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2e921e89470, moduleTitle=Front Oncol：不可切除的III期非小细胞肺癌同期或续贯放化疗后Durvalumab维持治疗的真实世界、多中心、观察性回顾性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2e921e89470)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866287, encodeId=34a0186628e13, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet oncol：3期| 达雷妥尤单抗+来那度胺一线治疗不适移植的多发性骨髓瘤的疗效可期！, objectType=article, longId=218592, objectId=454b218592dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=454b218592dd, replyNumber=0, likeNumber=92, createdTime=2022-07-18, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=454b218592dd, moduleTitle=Lancet oncol：3期| 达雷妥尤单抗+来那度胺一线治疗不适移植的多发性骨髓瘤的疗效可期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=454b218592dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866125, encodeId=bd3918661259f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet oncol：卡瑞珠单抗+吉西他滨+顺铂或可成为中国复发/转移性鼻咽癌的新标准一线疗法, objectType=article, longId=213189, objectId=500e213189ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=500e213189ee, replyNumber=0, likeNumber=65, createdTime=2022-05-07, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=500e213189ee, moduleTitle=Lancet oncol：卡瑞珠单抗+吉西他滨+顺铂或可成为中国复发/转移性鼻咽癌的新标准一线疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=500e213189ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866160, encodeId=cef3186616071, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：三种131I-间碘苯甲基胍方案治疗神经母细胞瘤的缓解率！, objectType=article, longId=214521, objectId=90a9214521fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90a9214521fb, replyNumber=0, likeNumber=80, createdTime=2022-01-18, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90a9214521fb, moduleTitle=J Clin Oncol：三种131I-间碘苯甲基胍方案治疗神经母细胞瘤的缓解率！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90a9214521fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866218, encodeId=099b1866218a8, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Thorac Oncol：达拉非尼+曲美替尼治疗转移性BRAF V600E突变非小细胞肺癌的疗效：5年生存结果更新, objectType=article, longId=217037, objectId=f9ca21e03751, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9ca21e03751, replyNumber=0, likeNumber=53, createdTime=2021-11-24, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9ca21e03751, moduleTitle=J Thorac Oncol：达拉非尼+曲美替尼治疗转移性BRAF V600E突变非小细胞肺癌的疗效：5年生存结果更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9ca21e03751)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866447, encodeId=68bb186644e7f, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ther Adv Med Oncol：韩国大型真实世界数据评估雷莫芦单抗（Ramucirumab）联合紫杉醇作为二线治疗晚期胃或胃食管交界处腺癌患者的疗效(KCSG-ST19-16), objectType=article, longId=293431, objectId=ec882934312f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec882934312f, replyNumber=0, likeNumber=65, createdTime=2022-03-01, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec882934312f, moduleTitle=Ther Adv Med Oncol：韩国大型真实世界数据评估雷莫芦单抗（Ramucirumab）联合紫杉醇作为二线治疗晚期胃或胃食管交界处腺癌患者的疗效(KCSG-ST19-16), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec882934312f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866414, encodeId=c41d18664140b, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：WEE1抑制剂在TP53和RAS突变转移性结直肠癌中有效:一项比较Adavosertib (AZD1775)和主动监测的随机试验(FOCUS4-C), objectType=article, longId=291939, objectId=aea92919392a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aea92919392a, replyNumber=0, likeNumber=58, createdTime=2022-05-13, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aea92919392a, moduleTitle=J Clin Oncol：WEE1抑制剂在TP53和RAS突变转移性结直肠癌中有效:一项比较Adavosertib (AZD1775)和主动监测的随机试验(FOCUS4-C), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aea92919392a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866350, encodeId=1516186635044, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：替莫唑胺联合阿帕替尼治疗复发性胶质母细胞瘤的疗效和安全性, objectType=article, longId=220476, objectId=41ac2204e60d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41ac2204e60d, replyNumber=0, likeNumber=0, createdTime=2022-08-04, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41ac2204e60d, moduleTitle=Front Oncol：替莫唑胺联合阿帕替尼治疗复发性胶质母细胞瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41ac2204e60d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866230, encodeId=7be0186623079, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：来曲唑延长治疗5年可显著提高已绝经的早期乳腺癌患者的生存预后, objectType=article, longId=217300, objectId=305521e30070, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=305521e30070, replyNumber=0, likeNumber=85, createdTime=2021-12-19, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=305521e30070, moduleTitle=Lancet Oncol：来曲唑延长治疗5年可显著提高已绝经的早期乳腺癌患者的生存预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=305521e30070)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866433, encodeId=c1b1186643319, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：T分期和病理淋巴结数目的结合为淋巴结受累的早期宫颈癌提供更好的预后鉴别, objectType=article, longId=293003, objectId=60ad29300376, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60ad29300376, replyNumber=0, likeNumber=33, createdTime=2022-05-28, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60ad29300376, moduleTitle=Front Oncol：T分期和病理淋巴结数目的结合为淋巴结受累的早期宫颈癌提供更好的预后鉴别, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60ad29300376)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866151, encodeId=1311186615113, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：Pegaspargase和Calaspargase Pegol治疗儿童ALL的疗效和毒性, objectType=article, longId=214106, objectId=eb67214106de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb67214106de, replyNumber=0, likeNumber=0, createdTime=2021-10-07, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb67214106de, moduleTitle=J Clin Oncol：Pegaspargase和Calaspargase Pegol治疗儿童ALL的疗效和毒性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb67214106de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866242, encodeId=c23b18662420c, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：携带ATM致病性变异的个体患胰腺癌的风险升高了六倍余！, objectType=article, longId=217482, objectId=829221e482ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=829221e482ff, replyNumber=0, likeNumber=61, createdTime=2021-11-21, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=829221e482ff, moduleTitle=JAMA Oncol：携带ATM致病性变异的个体患胰腺癌的风险升高了六倍余！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=829221e482ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Oncol

2020-05-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后

2022-03-18

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：芳香酶抑制剂对比他莫昔芬治疗绝经前的ER阳性早期乳腺癌

2022-03-12

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet oncol：派姆单抗联合西妥昔单抗治疗复发性/转移性HNSCC的疗效和安全性

2022-01-27

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Oncologist：RAS/BRAF野生型转移性结直肠癌(mCRC)患者中以抗EGFR为基础的再诱导治疗的疗效

2023-01-01

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：Afatinib（阿法替尼）治疗EGFR突变阳性的局部晚期或转移性非小细胞肺癌（NSCLC）的疗效：来自3个IIIb期研究的合并分析

2022-07-12

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：本妥昔单抗维多丁可显著减少高危型霍奇金淋巴瘤儿童患者的放疗剂量且不影响疗效

2021-04-30

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：伴有肺胸膜侵犯(VPI)的IB期NSCLC (≦3 cm)患者的手术治疗模式和预后

2022-10-07

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Thorac Oncol：Durvalumab +tremelimumab联合或不联合化疗一线治疗驱动基因阴性的转移性NSCLC患者的疗效和安全性

2022-11-04

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：不可切除的III期非小细胞肺癌同期或续贯放化疗后Durvalumab维持治疗的真实世界、多中心、观察性回顾性研究

2022-06-20

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet oncol：3期| 达雷妥尤单抗+来那度胺一线治疗不适移植的多发性骨髓瘤的疗效可期！

2022-07-18

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet oncol：卡瑞珠单抗+吉西他滨+顺铂或可成为中国复发/转移性鼻咽癌的新标准一线疗法

2022-05-07

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：三种131I-间碘苯甲基胍方案治疗神经母细胞瘤的缓解率！

2022-01-18

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Thorac Oncol：达拉非尼+曲美替尼治疗转移性BRAF V600E突变非小细胞肺癌的疗效：5年生存结果更新

2021-11-24

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ther Adv Med Oncol：韩国大型真实世界数据评估雷莫芦单抗（Ramucirumab）联合紫杉醇作为二线治疗晚期胃或胃食管交界处腺癌患者的疗效(KCSG-ST19-16)

2022-03-01

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：WEE1抑制剂在TP53和RAS突变转移性结直肠癌中有效:一项比较Adavosertib (AZD1775)和主动监测的随机试验(FOCUS4-C)

2022-05-13

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：替莫唑胺联合阿帕替尼治疗复发性胶质母细胞瘤的疗效和安全性

2022-08-04

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：来曲唑延长治疗5年可显著提高已绝经的早期乳腺癌患者的生存预后

2021-12-19

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：T分期和病理淋巴结数目的结合为淋巴结受累的早期宫颈癌提供更好的预后鉴别

2022-05-28

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：Pegaspargase和Calaspargase Pegol治疗儿童ALL的疗效和毒性

2021-10-07

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：携带ATM致病性变异的个体患胰腺癌的风险升高了六倍余！

2021-11-21

科室
- - 订阅+
  - 更多科室
工具
服务